Technology & Software Global On demand · 24-48h

Global Hereditary Disease Testing Market Strategic Research Report

Name: Global Hereditary Disease Testing Market Strategic Research Report
Brand: Market Research Reports, Inc.
Price: 3500 USD
Availability: PreOrder

Global Hereditary Disease Testing Market Strategic Research …

$3,500 USD

Strategic Research Report

Global Hereditary Disease Testing Market

$1.13B2025

12.8%CAGR

2032Forecast

Market Research Reports · Global

Market Research Reports Intelligence Series

By Type: Hereditary Cancer Testing, Hereditary Non-cancer Testing

By Application: Hospital, Clinic, Laboratory, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Myriad Genetics, Invitae, Illumina, Natera, Laboratory Corporation of America Holdings, F. Hoffmann-La Roche, Quest Diagnostics, CooperSurgical, Agilent Technologies, Thermo Fisher Scientific, Twist Bioscience, Sophia Genetics, Fulgent Genetic, Medgenome, CENTOGENE

Region: Global

Formats: PDF, Excel, Word & PowerPoint

Base year: 2025 · forecast to 2032

Length: 117 pages

Market size 2025

$1.13B

Billion USD

Forecast CAGR

12.8%

2025-2032

Forecast 2032

$2.6B

Projected

Gebieden

Asia Pacific · Latin America · MEA · Europe · North America

Overzicht

Scope of the Report

The global Hereditary Disease Testing market size is predicted to grow from US$ 1,127 million in 2025 to US$ 2,573 million in 2032; it is expected to grow at a CAGR of 12.8% from 2026 to 2032.

Hereditary disease testing is a medical detection method that analyzes an individual’s genetic material (DNA, RNA, or chromosomes) to identify genetic variations associated with inherited diseases. It helps assess disease risk, diagnose conditions, or guide prevention and treatment.

The global market for hereditary disease testing is experiencing rapid growth, driven by factors such as technological advancements, increased awareness of genetic diseases, and the expansion of personalized medicine.

North America has the largest market share in the global hereditary disease testing market. This is because of its advanced healthcare infrastructure, high - level medical technology, and strong awareness of hereditary diseases among the population. For example, the United States has a large number of leading genetic testing companies and research institutions.

Asia - Pacific is the region with the fastest - growing market. Driven by the continuous increase in healthcare investments and the active promotion of genomic research in countries such as China and India, the market demand is constantly expanding.

This report presents a comprehensive overview of the global Hereditary Disease Testing market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

Hereditary Cancer Testing
Hereditary Non-cancer Testing

Segment by Testing Content

Chromosomal Testing
Gene Mutation Testing
Genome/Exome Sequencing
Carrier Screening Panels

Segment by Detection Object

Aldult
Child

Segment by Application

Hospital
Clinic
Laboratory
Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Hereditary Disease Testing market:

Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
Distributors, channel partners and end users in Hospital, Clinic, Laboratory evaluating demand and sourcing options
Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Hereditary Disease Testing Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports

Market size CAGR 12.8%

Regional growth momentum

Market share by segment

Key metrics

Base value

$1.13B

2025

Forecast

$2.6B

2032

CAGR

12.8%

2025–2032

Gebieden

global

Key companies

Myriad GeneticsInvitaeIlluminaNateraLaboratory Corporation of America HoldingsF. Hoffmann-La RocheQuest DiagnosticsCooperSurgical

Segments covered in this report

By Type

Hereditary Cancer TestingHereditary Non-cancer Testing

By Application

HospitalClinicLaboratoryOthers

Click a chapter to expand

01Executive Summary

02Industry Overview & Forecast

2.1.1 Market Definition and Scope
2.1.2 Market Size and Growth Forecast
2.1.3 Volume Analysis
2.1.4 Segment Outlook by Type
2.1.5 Segment Outlook by Application
2.1.6 Regional Outlook
2.1.7 Structural Developments Shaping the Forecast
2.1.8 Forecast Risks and Sensitivities

03Market Segmentation by Type

3.1 Market Segmentation by Type
3.1.1 Market by Type Overview
3.1.2 Hereditary Cancer Testing
3.1.3 Hereditary Non-cancer Testing
3.1.4 Volume Analysis

04Market Segmentation by Application

4.1 Market Segmentation by Application
4.1.1 Market by Application Overview
4.1.2 Hospital
4.1.3 Clinic
4.1.4 Laboratory
4.1.5 Others
4.1.6 Volume Analysis

05Regional Market Forecast

Asia Pacific
North America
Europe
Middle East & Africa
Latin America

06Country-Level Market Forecast

6.1 Asia Pacific
6.1.1 China
6.1.2 Japan
6.1.3 Korea
6.1.4 Southeast Asia
6.1.5 India
6.1.6 Australia
6.1.7 Rest of Asia Pacific
6.2 North America
6.2.1 United States
6.2.2 Canada
6.2.3 Mexico
6.2.4 Rest of North America
6.3 Europe
6.3.1 Germany
6.3.2 France
6.3.3 UK
6.3.4 Italy
6.3.5 Russia
6.3.6 Rest of Europe
6.4 Middle East & Africa
6.4.1 Egypt
6.4.2 South Africa
6.4.3 Israel
6.4.4 Turkey
6.4.5 GCC Countries
6.4.6 Rest of Middle East & Africa
6.5 Latin America
6.5.1 Brazil
6.5.2 Rest of Latin America

07Growth Drivers & Inhibitors

7.1 Growth Drivers & Inhibitors
7.1.1 Section Overview
7.1.2 Growth Drivers
7.1.3 Growth Inhibitors
7.1.4 Driver and Inhibitor Impact Assessment
7.1.5 Analyst Perspective

08Key Company Profiles

8.1 Myriad Genetics
8.1.1 Company Overview
8.1.2 Key Products & Segments
8.1.3 Financial Performance (2023–2025)
8.1.4 Business Strategy
8.1.5 SWOT Analysis
8.1.6 Strategic Implications (2026–2032)
8.2 Invitae
8.2.1 Company Overview
8.2.2 Key Products & Segments
8.2.3 Financial Performance (2023–2025)
8.2.4 Business Strategy
8.2.5 SWOT Analysis
8.2.6 Strategic Implications (2026–2032)
8.3 Illumina
8.3.1 Company Overview
8.3.2 Key Products & Segments
8.3.3 Financial Performance (2023–2025)
8.3.4 Business Strategy
8.3.5 SWOT Analysis
8.3.6 Strategic Implications (2026–2032)
8.4 Natera
8.4.1 Company Overview
8.4.2 Key Products & Segments
8.4.3 Financial Performance (2023–2025)
8.4.4 Business Strategy
8.4.5 SWOT Analysis
8.4.6 Strategic Implications (2026–2032)
8.5 Laboratory Corporation of America Holdings
8.5.1 Company Overview
8.5.2 Key Products & Segments
8.5.3 Financial Performance (2023–2025)
8.5.4 Business Strategy
8.5.5 SWOT Analysis
8.5.6 Strategic Implications (2026–2032)
8.6 F. Hoffmann-La Roche
8.6.1 Company Overview
8.6.2 Key Products & Segments
8.6.3 Financial Performance (2023–2025)
8.6.4 Business Strategy
8.6.5 SWOT Analysis
8.6.6 Strategic Implications (2026–2032)
8.7 Quest Diagnostics
8.7.1 Company Overview
8.7.2 Key Products & Segments
8.7.3 Financial Performance (2023–2025)
8.7.4 Business Strategy
8.7.5 SWOT Analysis
8.7.6 Strategic Implications (2026–2032)
8.8 CooperSurgical
8.8.1 Company Overview
8.8.2 Key Products & Segments
8.8.3 Financial Performance (2023–2025)
8.8.4 Business Strategy
8.8.5 SWOT Analysis
8.8.6 Strategic Implications (2026–2032)
8.9 Agilent Technologies
8.9.1 Company Overview
8.9.2 Key Products & Segments
8.9.3 Financial Performance (2023–2025)
8.9.4 Business Strategy
8.9.5 SWOT Analysis
8.9.6 Strategic Implications (2026–2032)
8.10 Thermo Fisher Scientific
8.10.1 Company Overview
8.10.2 Key Products & Segments
8.10.3 Financial Performance (2023–2025)
8.10.4 Business Strategy
8.10.5 SWOT Analysis
8.10.6 Strategic Implications (2026–2032)
8.11 Twist Bioscience
8.11.1 Company Overview
8.11.2 Key Products & Segments
8.11.3 Financial Performance (2023–2025)
8.11.4 Business Strategy
8.11.5 SWOT Analysis
8.11.6 Strategic Implications (2026–2032)
8.12 Sophia Genetics
8.12.1 Company Overview
8.12.2 Key Products & Segments
8.12.3 Financial Performance (2023–2025)
8.12.4 Business Strategy
8.12.5 SWOT Analysis
8.12.6 Strategic Implications (2026–2032)
8.13 Fulgent Genetic
8.13.1 Company Overview
8.13.2 Key Products & Segments
8.13.3 Financial Performance (2023–2025)
8.13.4 Business Strategy
8.13.5 SWOT Analysis
8.13.6 Strategic Implications (2026–2032)
8.14 Medgenome
8.14.1 Company Overview
8.14.2 Key Products & Segments
8.14.3 Financial Performance (2023–2025)
8.14.4 Business Strategy
8.14.5 SWOT Analysis
8.14.6 Strategic Implications (2026–2032)
8.15 CENTOGENE
8.15.1 Company Overview
8.15.2 Key Products & Segments
8.15.3 Financial Performance (2023–2025)
8.15.4 Business Strategy
8.15.5 SWOT Analysis
8.15.6 Strategic Implications (2026–2032)

09Competitive Landscape

9.1 Competitive Landscape Overview
9.2 Competitive Intensity Assessment
9.3 Key Player Strategies & Positioning
9.4 Competitive Dynamics & Strategic Outlook
9.4.1 Emerging Competitive Threats
9.4.2 Consolidation vs. Fragmentation Outlook
9.4.3 Competitive Response Matrix
9.4.4 Strategic Recommendations, 2026–2032

10Porter's Five Forces Analysis

10.1 Threat of New Entrants
10.2 Bargaining Power of Buyers
10.3 Bargaining Power of Suppliers
10.4 Threat of Substitutes
10.5 Competitive Rivalry

11PESTLE Analysis

11.1 Political
11.2 Economic
11.3 Social and Demographic
11.4 Technological
11.5 Legal and Regulatory
11.6 Environmental
11.7 Strategic Implications of the PESTLE Assessment

12SWOT Analysis

13Future Trends & Outlook

13.1 Future Trends & Outlook
13.1.1 Trend Summary and Commercial Maturity Assessment
13.1.2 Technology and Innovation Trends
13.1.3 Long-Term Market Outlook
13.1.4 Investment & M&A Activity Outlook
13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Hereditary Disease Testing market?

The global Hereditary Disease Testing market is estimated at US$ 1.13 billion in 2025 (base year) and is projected to reach US$ 2.57 billion by 2032.

How fast is the Hereditary Disease Testing market expected to grow?

The market is expected to grow at a CAGR of 12.8% from 2026 to 2032, expanding from US$ 1.13 billion in 2025 to US$ 2.57 billion in 2032, roughly 2.3 times its base-year value.

What does the Hereditary Disease Testing market cover?

What are the main segments of the Hereditary Disease Testing market by type?

By type, the market is segmented into Hereditary Cancer Testing and Hereditary Non-cancer Testing.

Which applications drive demand in the Hereditary Disease Testing market?

Key applications covered include Hospital, Clinic, Laboratory and Others.

Who are the key players in the Hereditary Disease Testing market?

Key players profiled include Myriad Genetics, Invitae, Illumina, Natera, Laboratory Corporation of America Holdings, F. Hoffmann-La Roche, Quest Diagnostics and CooperSurgical, among 15 companies covered in total.

Which regions and countries are covered for Hereditary Disease Testing?

The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.

What is driving growth in the Hereditary Disease Testing market?

Who should buy the Hereditary Disease Testing market report?

The report is intended for manufacturers and solution providers, distributors and end users in Hospital, Clinic and Laboratory, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Hereditary Disease Testing market.

What license options are available for this report?

The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.